<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To evaluate our results using photodynamic therapy (<z:chebi fb="7" ids="53228">PDT</z:chebi>) for the treatment of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or superficial <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (T1 N0 M0) in patients with <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: We retrospectively reviewed our clinical experience with 48 patients (34 patients with high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and 14 patients with superficial <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo>) who had been referred for <z:chebi fb="7" ids="53228">PDT</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Initial evaluation included computed tomography and standard and high-frequency catheter endosonography </plain></SENT>
<SENT sid="3" pm="."><plain>Follow-up endoscopy was performed 4 to 6 weeks after <z:chebi fb="7" ids="53228">PDT</z:chebi> with ablation of any residual glandular mucosa, using the <z:chebi fb="17" ids="49474,49475">argon</z:chebi> plasma coagulator </plain></SENT>
<SENT sid="4" pm="."><plain>Patients were then followed up indefinitely every 3 to 6 months with computed tomography, endosonography, and endoscopic surveillance </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: The median series follow-up was 18.5 months (range, 1-56 months) </plain></SENT>
<SENT sid="6" pm="."><plain>Apparent complete photoablation of Barrett mucosa and/or superficial <z:hpo ids='HP_0002664'>neoplasm</z:hpo> was documented in 47 of 48 cases </plain></SENT>
<SENT sid="7" pm="."><plain>Complications included symptomatic strictures (11 patients), <z:hpo ids='HP_0000992'>photosensitivity</z:hpo> (7 patients), <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> (1 patient) or recurrent <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo> (1 patient), and self-limited esophageal <z:mpath ids='MPATH_81'>perforation</z:mpath> (1 patient) </plain></SENT>
<SENT sid="8" pm="."><plain>Failure to ablate T1 N0 M0 <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> occurred in 1 patient </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Porfimer <z:chebi fb="199" ids="26708">sodium</z:chebi> <z:chebi fb="7" ids="53228">PDT</z:chebi> appears to eradicate dysplastic Barrett mucosa and <z:hpo ids='HP_0002664'>neoplasia</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>These results are promising; however, long-term studies are needed to document the efficacy of <z:chebi fb="7" ids="53228">PDT</z:chebi> in reducing the morbidity and mortality in such patients </plain></SENT>
</text></document>